Effect of mannosylated derivatives on HIV-1 infection of macrophages and lymphocytes.
We previously demonstrated that gp120/160 (Env) of HIV-1 interact in a carbohydrate-specific manner with mannosyl/N-acetylglucosaminyl derivatives and that HIV-1LAI infection of monocytic U937 and lymphoid CEM cells was inhibited by CD4-free Concanavalin A-reactive glycopeptides from U937 cells. We report here that the natural glycoproteins bovine fetuin and asialofetuin, human orosomucoid and alpha-fetoprotein, and mannan, which all specifically interact with Env, inhibited infection of primary macrophages by macrophage-tropic HIV-1 strains, whereas dextran had no such effect. This activity was conserved if fetuin, asialofetuin, or orosomucoid were heat-treated, which rules out the role of their three-dimensional structure. Orosomucoid and mannan partially inhibited Env binding to macrophages but not to U937 or CEM cells. This indicates that Env does not bind in the same manner to primary macrophages and to immortalized CD4+ cells, and that orosomucoid and mannan act at CD4-independent stages of virus binding to macrophages. Mannan also inhibited Env binding to surface glycopeptides obtained after trypsin treatment of macrophages. Furthermore, orosomucoid and fetuin interacted with, and they inhibited the binding of a V3 loop B clade consensus peptide to several macrophage membrane proteins, including two 36 and 42 kDa proteins. These data indicate that these glycoproteins interfere with post-binding events during HIV-1 infection of primary macrophages. In contrast, the compounds did not affect infection of U937 or CEM cells by T-cell tropic HIV-1LAI nor infection of peripheral blood lymphocytes by HIV-1LAI or HIV-1(Ba-L). Thus, carbohydrate-specific inhibition of HIV infection depends on the cell type more than on the viral strain, and differences in the glycan structure of cell-type-specific cofactors may be important for HIV entry into cells.
Seddiki
N
N
Laboratoire de Biologie Cellulaire, Université Paris-Nord, Bobigny, France.
Rabehi
L
L
Benjouad
A
A
Saffar
L
L
Ferriere
F
F
Gluckman
J C
JC
Gattegno
L
L
D000818:Animals; D001212:Asialoglycoproteins / Q000494:pharmacology; D001667:Binding, Competitive; D002417:Cattle; D002478:Cells, Cultured; D060748:Fetuins; D006023:Glycoproteins / Q000494:pharmacology*; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D019302:HIV Envelope Protein gp160 / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development*; D006358:Hot Temperature; D006801:Humans; D008214:Lymphocytes / Q000821:virology*; D008264:Macrophages / Q000821:virology*; D008351:Mannans / Q000494:pharmacology; D008358:Mannose; D008562:Membrane Glycoproteins / Q000378:metabolism; D009961:Orosomucoid / Q000494:pharmacology; D010446:Peptide Fragments / Q000378:metabolism; D014357:Trypsin / Q000494:pharmacology; D000509:alpha-Fetoproteins / Q000494:pharmacology
D001212:Asialoglycoproteins; D060748:Fetuins; D006023:Glycoproteins; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D008351:Mannans; D008562:Membrane Glycoproteins; D009961:Orosomucoid; D010446:Peptide Fragments; D000509:alpha-Fetoproteins; C017029:asialofetuin; D014357:Trypsin; D008358:Mannose